A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia (ARGX-113-2402)

Project: Clinical studiesClinical Study (Industry project)

Project Details

Short titleARGX-113-2402
StatusActive
Effective start/end date04.06.202531.05.2029

Fields of science

  • 302024 Haematology
  • 302055 Oncology